157 related articles for article (PubMed ID: 37196766)
1. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.
Zhang Y; Xiong X; Sun R; Zhu X; Wang C; Jiang B; Yang X; Li D; Fan G
J Biol Chem; 2023 Jun; 299(6):104825. PubMed ID: 37196766
[TBL] [Abstract][Full Text] [Related]
2. Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.
Zhu X; Liu H; Chen L; Wu C; Liu X; Cang Y; Jiang B; Yang X; Fan G
Cell Chem Biol; 2022 Nov; 29(11):1616-1629.e12. PubMed ID: 36323324
[TBL] [Abstract][Full Text] [Related]
3. HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
Fan G; Zhang S; Gao Y; Greer PA; Tonks NK
Genes Dev; 2016 Jul; 30(13):1542-57. PubMed ID: 27401557
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation.
Chen JJ; Jin JM; Gu WJ; Zhao Z; Yuan H; Zhou YD; Nagle DG; Xi QL; Zhang XM; Sun QY; Wu Y; Zhang WD; Luan X
Cancer Sci; 2023 May; 114(5):1958-1971. PubMed ID: 36692137
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
6. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
7. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
[TBL] [Abstract][Full Text] [Related]
8. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
9. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
11. FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
Fan G
Small GTPases; 2020 May; 11(3):155-159. PubMed ID: 29099290
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
Chen S; Chen Z; Lu L; Zhao Y; Zhou R; Xie Q; Shu Y; Lin J; Yu X; Wang Y
Eur J Med Chem; 2023 Jul; 255():115403. PubMed ID: 37119666
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
[TBL] [Abstract][Full Text] [Related]
14. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.
Vorderbruggen M; Velázquez-Martínez CA; Natarajan A; Karpf AR
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791105
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis-targeting chimera molecules targeting SHP2.
Yu D; Zheng M; Liu Y; Chen L; Li H
Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
17. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors.
Si R; Zhu H; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Chem; 2023 May; 134():106439. PubMed ID: 36842319
[TBL] [Abstract][Full Text] [Related]
20. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
